RetroSearch Browse

Home - News ( United States | United Kingdom | Italy | Germany ) - Football scores

Showing content from https://pubmed.ncbi.nlm.nih.gov/32392282/ below:

Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State

Observational Study

. 2020 Jun 23;323(24):2493-2502. doi: 10.1001/jama.2020.8630. Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State Elizabeth M Dufort², Tomoko Udo¹, Larissa A Wilberschied², Jessica Kumar², James Tesoriero², Patti Weinberg³, James Kirkwood², Alison Muse², Jack DeHovitz^{3 4}, Debra S Blog², Brad Hutton², David R Holtgrave¹, Howard A Zucker²

Affiliations

¹ University at Albany School of Public Health, State University of New York, Rensselaer.
² New York State Department of Health, Albany.
³ IPRO, Lake Success, New York.
⁴ Downstate Health Sciences University, State University of New York, Brooklyn.

PMID: 32392282
PMCID: PMC7215635
DOI: 10.1001/jama.2020.8630

Item in Clipboard

Observational Study

Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State

Eli S Rosenberg et al. JAMA. 2020.

. 2020 Jun 23;323(24):2493-2502. doi: 10.1001/jama.2020.8630. Authors Eli S Rosenberg¹, Elizabeth M Dufort², Tomoko Udo¹, Larissa A Wilberschied², Jessica Kumar², James Tesoriero², Patti Weinberg³, James Kirkwood², Alison Muse², Jack DeHovitz^{3 4}, Debra S Blog², Brad Hutton², David R Holtgrave¹, Howard A Zucker² Affiliations

¹ University at Albany School of Public Health, State University of New York, Rensselaer.
² New York State Department of Health, Albany.
³ IPRO, Lake Success, New York.
⁴ Downstate Health Sciences University, State University of New York, Brooklyn.

PMID: 32392282
PMCID: PMC7215635
DOI: 10.1001/jama.2020.8630

Item in Clipboard

Abstract

Importance: Hydroxychloroquine, with or without azithromycin, has been considered as a possible therapeutic agent for patients with coronavirus disease 2019 (COVID-19). However, there are limited data on efficacy and associated adverse events.

Objective: To describe the association between use of hydroxychloroquine, with or without azithromycin, and clinical outcomes among hospital inpatients diagnosed with COVID-19.

Design, setting, and participants: Retrospective multicenter cohort study of patients from a random sample of all admitted patients with laboratory-confirmed COVID-19 in 25 hospitals, representing 88.2% of patients with COVID-19 in the New York metropolitan region. Eligible patients were admitted for at least 24 hours between March 15 and 28, 2020. Medications, preexisting conditions, clinical measures on admission, outcomes, and adverse events were abstracted from medical records. The date of final follow-up was April 24, 2020.

Exposures: Receipt of both hydroxychloroquine and azithromycin, hydroxychloroquine alone, azithromycin alone, or neither.

Main outcomes and measures: Primary outcome was in-hospital mortality. Secondary outcomes were cardiac arrest and abnormal electrocardiogram findings (arrhythmia or QT prolongation).

Results: Among 1438 hospitalized patients with a diagnosis of COVID-19 (858 [59.7%] male, median age, 63 years), those receiving hydroxychloroquine, azithromycin, or both were more likely than those not receiving either drug to have diabetes, respiratory rate >22/min, abnormal chest imaging findings, O2 saturation lower than 90%, and aspartate aminotransferase greater than 40 U/L. Overall in-hospital mortality was 20.3% (95% CI, 18.2%-22.4%). The probability of death for patients receiving hydroxychloroquine + azithromycin was 189/735 (25.7% [95% CI, 22.3%-28.9%]), hydroxychloroquine alone, 54/271 (19.9% [95% CI, 15.2%-24.7%]), azithromycin alone, 21/211 (10.0% [95% CI, 5.9%-14.0%]), and neither drug, 28/221 (12.7% [95% CI, 8.3%-17.1%]). In adjusted Cox proportional hazards models, compared with patients receiving neither drug, there were no significant differences in mortality for patients receiving hydroxychloroquine + azithromycin (HR, 1.35 [95% CI, 0.76-2.40]), hydroxychloroquine alone (HR, 1.08 [95% CI, 0.63-1.85]), or azithromycin alone (HR, 0.56 [95% CI, 0.26-1.21]). In logistic models, compared with patients receiving neither drug cardiac arrest was significantly more likely in patients receiving hydroxychloroquine + azithromycin (adjusted OR, 2.13 [95% CI, 1.12-4.05]), but not hydroxychloroquine alone (adjusted OR, 1.91 [95% CI, 0.96-3.81]) or azithromycin alone (adjusted OR, 0.64 [95% CI, 0.27-1.56]), . In adjusted logistic regression models, there were no significant differences in the relative likelihood of abnormal electrocardiogram findings.

Conclusions and relevance: Among patients hospitalized in metropolitan New York with COVID-19, treatment with hydroxychloroquine, azithromycin, or both, compared with neither treatment, was not significantly associated with differences in in-hospital mortality. However, the interpretation of these findings may be limited by the observational design.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Dufort reported that her spouse has a Gilead Foundation-Focus HIV/HCV testing research grant. No other disclosures were reported.

Figures
Figure 1.. Sampling Strategy of COVID-19 Admissions…

Figure 1.. Sampling Strategy of COVID-19 Admissions in New York From Underlying Patient Cohort

COVID-19…

Figure 1.. Sampling Strategy of COVID-19 Admissions in New York From Underlying Patient Cohort

COVID-19 indicates coronavirus disease 2019; LOS, length of stay; SHIN-NY, State Health Information Network for NY.

Figure 2.. Model-Adjusted Estimated In-Hospital Mortality, by…

Figure 2.. Model-Adjusted Estimated In-Hospital Mortality, by Treatment Group

Graph is based on a Cox…

Figure 2.. Model-Adjusted Estimated In-Hospital Mortality, by Treatment Group

Graph is based on a Cox proportional hazards model. Sample sizes provided reflect the source data observed, which informed the creation of the model. Compared with the neither-drug group, none of the 3 treatment groups had statistically different rates of death, at α = .05: hydroxychloroquine + azithromycin, P = .31; hydroxychloroquine alone, P = .79; and azithromycin alone, P = .14.